Profile data is unavailable for this security.
About the company
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
- Revenue in USD (TTM)10.26m
- Net income in USD-45.48m
- Incorporated2000
- Employees48.00
- LocationCuris Inc128 Spring Street, Building C, Suite 500LEXINGTON 02421United StatesUSA
- Phone+1 (617) 503-6500
- Fax+1 (617) 503-6501
- Websitehttps://www.curis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promis Neurosciences Inc | 0.00 | -563.35k | 31.22m | 6.00 | -- | 4.29 | -- | -- | -0.1931 | -0.1931 | 0.00 | 0.2225 | 0.00 | -- | -- | 0.00 | -2.66 | -144.28 | -3.77 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -19.09m | 31.81m | 21.00 | -- | 1.20 | -- | -- | -1.77 | -1.77 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -48.91 | -28.83 | -52.88 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 31.89m | 22.00 | -- | 0.3482 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -8.82m | 32.21m | -- | -- | 43.15 | -- | -- | -0.2378 | -0.2378 | 0.00 | 0.0206 | 0.00 | -- | -- | -- | -56.73 | -- | -163.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.42m | 163.00 | -- | 0.1589 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.61m | 32.75m | 32.00 | -- | 0.5835 | -- | -- | -1.08 | -1.08 | 0.00 | 5.54 | 0.00 | -- | -- | -- | -16.17 | -31.68 | -16.64 | -33.95 | -- | -- | -- | -56,271.43 | -- | -- | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Passage Bio Inc | 0.00 | -68.80m | 33.11m | 58.00 | -- | 0.4553 | -- | -- | -1.17 | -1.17 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -48.97 | -48.56 | -56.34 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Curis Inc | 10.26m | -45.48m | 34.04m | 48.00 | -- | -- | -- | 3.32 | -7.81 | -7.81 | 1.76 | -1.45 | 0.1549 | -- | 3.52 | 213,729.20 | -68.68 | -37.25 | -94.06 | -41.12 | 98.68 | 96.05 | -443.35 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Carisma Therapeutics Inc | 20.27m | -63.80m | 35.40m | 107.00 | -- | -- | -- | 1.75 | -1.56 | -1.56 | 0.4927 | -0.2665 | 0.2723 | -- | -- | 189,420.60 | -85.73 | -30.87 | -101.81 | -34.47 | -- | -- | -314.78 | -255.66 | -- | -- | -- | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Elevation Oncology Inc | 0.00 | -41.95m | 35.78m | 29.00 | -- | 0.5159 | -- | -- | -0.807 | -0.807 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -40.67 | -- | -43.53 | -- | -- | -- | -- | -- | -- | -375.06 | 0.309 | -- | -- | -- | 51.93 | -- | -- | -- |
| NextCure Inc | 0.00 | -58.52m | 36.13m | 82.00 | -- | 0.4774 | -- | -- | -2.09 | -2.09 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -50.82 | -22.59 | -54.42 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 36.58m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -107.49m | 36.65m | 70.00 | -- | 0.3837 | -- | -- | -2.78 | -2.78 | 0.00 | 2.74 | 0.00 | -- | -- | 0.00 | -69.76 | -46.30 | -77.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| AN2 Therapeutics Inc | 0.00 | -60.70m | 36.75m | 41.00 | -- | 0.419 | -- | -- | -2.04 | -2.04 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -48.27 | -- | -53.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -16.26m | 37.18m | 5.00 | -- | 13.47 | -- | -- | -1.18 | -1.18 | 0.00 | 0.2005 | 0.00 | -- | -- | 0.00 | -147.61 | -- | -171.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Curis Inc's reporting currency: US Dollar USD
31.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Maverick Capital Ltd.as of 30 Sep 2024 | 582.27k | 9.74% |
| M28 Capital Management LPas of 30 Sep 2024 | 421.95k | 7.06% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 273.14k | 4.57% |
| CM Management LLCas of 30 Sep 2024 | 120.00k | 2.01% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 93.77k | 1.57% |
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Sep 2024 | 91.87k | 1.54% |
| Kingdon Capital Management LLCas of 30 Sep 2024 | 90.00k | 1.51% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 67.00k | 1.12% |
| Geode Capital Management LLCas of 30 Sep 2024 | 65.31k | 1.09% |
| Focused Wealth Management, Inc.as of 30 Sep 2024 | 54.07k | 0.90% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
